I
n recent years red blood cell (RBC) transfusion requirements in western nations has been increasing because of the increasing burden of chronic disease in an aging population, improvement in life-support technology, and blood-intensive surgical procedures (1, 2) . In the United States alone, nearly 15 million units of blood are donated and 13 million units are transfused annually (2) . For much of the last century, RBC transfusion has been viewed as having obvious clinical benefit. However, over the last 20 yrs RBC transfusion practice has come under increased scrutiny. Initially, this was driven by concerns over transfusion-related infections, human immunodeficiency virus in particular. Although the risk of transfusiontransmitted infections has received considerable attention, the risks of this complication, with modern blood banking techniques is now exceedingly remote (3) . On the other hand, it is now becoming clear that there are other important, less recognized risks of RBC transfusion related to RBC storage effects and to immunomodulating effects of RBC transfusions, which occur in almost all recipients (4) . These immunomodulating effects may increase the risk of the recipients developing nosocomial infections, acute lung injury, and the possible development of autoimmune diseases later in life (4, 5) . In recent years, the recognition of these risks has led to a more critical examination of the benefits associated with RBC transfusion. This is particularly important in critically ill, injured, and postoperative patients, with data in both adults and children suggesting equivalence, and in some groups superior clin-ical outcomes with a lower as opposed to "standard" transfusion thresholds (6, 7) .
Despite the increased scrutiny of transfusion practices, RBC transfusions remain common with up to 45% of patients being transfused in the intensive care unit (ICU) (8, 9) . The goal of this systematic review was (1) to evaluate the association between RBC transfusions and clinical outcome among hospitalized patients, and (2) to determine which patients (if any) may benefit from a RBC transfusion. We restricted this analysis to adult patients. The primary outcome was mortality, however, secondary outcomes included acquired infections, acute respiratory distress syndrome (ARDS), and multiorgan dysfunction syndrome. As the Canadian Critical Care Trials Group study (Transfusion Requirements in Critical Care [TRICC] ) (6) is the only prospective, adequately powered, randomized study which has investigated the impact of blood transfusion on patient outcome, our analysis was limited to observational studies. Although meta-analysis of randomized control studies are preferable to meta-analysis of observational studies, a systematic review of observational studies provide a tool for synthesizing clinical data in the absence of randomized controlled studies. Our meta-analysis was conducted in accord with the consensus recommendations by the Meta-analysis of Observational Studies in Epidemiology Group (10) .
METHODS

Identification of Trials.
The analysis was restricted to those observational studies that performed multivariate analysis with mortality and/or the risk of infections, multiorgan dysfunction syndrome, or ARDS as the endpoints. The aim was to identify all relevant observational trials that reported the impact of RBC transfusion on these clinical outcomes. A multimethod approach was used to identify relevant studies. The National Library of Medicine's MEDLINE database was searched for relevant studies in any language published between 1966 and June 2007 using the following medical subject headings and keywords: blood transfusion (explode), erythrocyte, AND mortality, ARDS, infection, multiple organ failure, critical care, intensive care, "wound or injury," surgery, and "all adult." In addition, Embase and the Cochrane Database of Systematic Reviews were searched. Bibliographies of all selected articles and review articles that included information on RBC transfusion were reviewed for other relevant articles. This search strategy was done iteratively, until no new potential citations were found on review of the reference lists of retrieved articles.
Data Extraction and Analysis. Both authors independently abstracted data from all studies using a standardized form. Data were abstracted on study design, study size, population, and the effect of blood transfusion on the end points of interest. In addition to the major outcome variables, the myocardial infarction rate and neurologic outcome scores were recorded in the neurosurgical and cardiac studies, respectively. ARDS were defined according to the American-European Consensus Committee Report (11) , and infection and sepsis were defined according to the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference (12) . The hospital mortality was recorded. The overall risks vs. benefits of RBC transfusion on patient outcome in each study was classified as (1) risks outweigh benefits, (2) neutral risk, and (3) benefits outweigh risks. This assessment was based on the study end points, such that if the risk of complications or death was statistically higher with blood transfusion, the risks were considered to outweigh the benefits. Likewise, if any outcome variable statistically favored blood transfusion (in the absence of any harmful effect) the benefits of RBC transfusion were considered to outweigh the risks. A study was considered neutral risk if blood transfusion had neither beneficial nor harmful effects. The reinfarction rate and neurologic outcome scores were additionally used in the assessment of the cardiac and neurosurgical studies, respectively. Disagreements regarding values or analysis were resolved by discussion between the reviewers.
To quantitate the effect of blood transfusions on the end points of interest, the odds ratio (OR) and 95% confidence interval (95% CI) for the observed effect was recorded if reported. Comprehensive Meta-analysis 2.0 (Biostat, Englewood, NJ) was used for all analyses; a p value of 0.05 (two-sided) was considered significant. We calculated the Cochran Q statistic to test for statistical heterogeneity. Values of Q significantly Ͼ0 (p Ͻ 0.1) were considered evidence of heterogeneity. Because of anticipated heterogeneity between studies, the random-effects model was used to determine the pooled OR, using the adjusted OR and 95% CI, of each study. Sensitivity analysis was done by grouping patients according to major diagnostic groups as follows: trauma, general surgery, cardiac surgery, neurosurgery, orthopedic surgery, acute coronary syndrome, and general ICU patients.
RESULTS
The search strategy generated 571 citations. Of those, 523 did not report the end points of interest or were not relevant and were excluded. A total of 48 articles from 45 studies, which specifically reported the association between RBC transfusion and one or more relevant end points were identified and included in the analysis (8, 9, . The results from one study (8) had three separate subgroup analyses reported (56, 57, 60). The number of trials evaluated at each stage of the evaluation is illustrated in Figure 1 . A summary of the studies is listed in Table 1 . In total 272,596 patients were included in the 45 studies; with a median of 687 patients/study (range, 63 to 78,974). The studies included trauma, general surgery, cardiac surgery, and neurosurgery, orthopedic, cardiac, and general ICU patients. No study reported the use of leukodepleted blood. There were no disagreements between the two reviewers as to study inclusion or data end point analysis.
In 42 of the 45 studies the risks of RBC transfusion outweighed the benefits, the risk was neutral in two studies, with the benefits outweighing the risks in a subgroup of a single study (elderly patients 
DISCUSSION
Our study suggests that across a broad spectrum of high risk hospitalized patients, RBC transfusions seem to be associated with increased morbidity and mortality. This was true even in trauma patients, those most likely to benefit from RBC transfusion. The reasons for the apparent lack of benefit of RBC transfusions in the patients included in this metaanalysis cannot be answered from this review. However, recent interest has focused on immunomodulating effects of transfused RBCs and RBC storage lesions (age of transfused RBCs) as possible mechanisms. It has been suggested that leukodepleted blood may have less immunomodulating properties and hence, reduce the complications associated with the transfusion of nonleukodepleted blood (4, 61, 62) . However, there is still some debate as to the benefit of leukoreduction (63) . Removal of leukocytes from red cell transfusions may have a small but potentially important effect on clinical outcomes, however, cost-effectiveness of universal leukoreduction has yet to be proven, especially in lower risk populations. It should be recognized that the studies included in our review were performed with nonleukodepleted blood. Similarly, age of transfused RBCs has also been suggested as possible explanation for some of the adverse effects associated with RBC transfusion. Numerous abnormalities have been associated with storage of RBCs, and some studies have suggested that transfusion of "older" RBCs may be associated with adverse effects (64 -67) . If age of transfused RBCs is, in fact, important it would have major ramifications on the already limited blood supply. At this point only limited clinical evidence is available and thus, a definitive clinical trial is necessary to answer this question.
The results of our study need to be interpreted with caution due to the nature of the studies included in our metaanalysis. Observational studies lack the experimental element of random allocation to an intervention and therefore, rely on the association between differences in one characteristic (RBC transfusion) and differences in outcome. Although multivariate analysis may attempt to correct for imbalances, between those exposed and not exposed to the characteristic of interest (RBC transfusion) inherent bias, may be difficult to eliminate. It could therefore be argued that blood transfusion itself is a marker for severity of illness, which cannot be adjusted by multivariate analysis. In addition, observational studies vary considerably in design and analysis. In analyzing a systematic review of observational studies, qualitative clinical endpoints (infections, ARDS, risk/benefit ratio) may therefore be as important as quantitative end-points (68 -70) . It is important to recognize that we were able to identify only a single study in which a subgroup of patients seemed to benefit from RBC transfusion. In the vast majority of studies, the risks associated with blood transfusion outweighed the benefits. This is remarkable, considering the number of patients who receive a RBC transfusion worldwide on a daily basis. Although the pooled OR for mortality and infectious complications should be interpreted with some caution because of heterogeneity between studies, the studies are notable for the consistent direction (harm) of the treatment effect. This suggests that the findings are likely to be true (68 -70) . As is evident from Figures 2 and 3, the differences in the patient populations largely accounts for the variation in the magnitude of the treatment effect (harm) and the heterogeneity between studies.
TRICC (6) is the only prospective, adequately powered, randomized study, which has investigated the impact of blood transfusion on outcome in adult patients (6) . The TRICC study compared a "liberal (10 g/dL)" vs. "restricted (7g/dL)" transfusion trigger threshold in 838 ICU patients. In this study, the restrictive transfusion threshold was at least equivalent, and in some patients (adults Ͻ55 yrs of age or Acute Physiology and Chronic Health Evaluation score Ͻ20) safer than the more liberal transfusion threshold. A more recent study in pediatric patients reported similar results (7). Our analysis, in combination with these trials, raises questions regarding the validity of the historic assumption that RBC transfusion is beneficial for critically ill, injured, and postoperative patients with anemia. Because of the observational nature of the studies included in our analysis, additional prospective studies are required to test the hypothesis that limiting blood transfusions reduces infections complications, ARDS, organ failure, and overall mortality in high-risk hospitalized patients. It should also be recognized that the TRICC study had no control group receiving routine care and studied two arbitrary fixed treatments for a usually titrated therapy (71) . The American Association of Blood Banking has recommended titrating transfusion requirements to parameters of severity of illness rather than arbitrarily defined hemoglobin levels (72) . This recommendation is in agreement with the more recent recommendations of the American Society of Anesthesiologists Task Force, (73) and the Canadian Guidelines which suggest "There is no single value of hemoglobin concentration that justifies or requires transfusion; an evaluation of the patient's clinical situation should also be a factor in the decision" (74) .
In the absence of acute bleeding, are there any patients who benefit from RBC transfusion or "When do the risks of anemia outweigh the hazards of transfusion?" In health, the amount of oxygen delivered to the whole body exceeds resting oxygen requirements almost four- fold. An isolated decrease in hemoglobin concentration to 10 g/dL, with all other parameters remaining constant, will result in an oxygen delivery that remains approximately twice that of the resting oxygen consumption. Furthermore, humans have a remarkable ability to adapt to anemia by increasing cardiac output (in the absence of volume depletion), increasing microcirculatory density, and by increasing red cell synthesis of 2,3-diphosphoglycerate with a resultant shift of the oxyhemoglobin dissociation curve (aids oxygen unloading) and by increasing oxygen extraction. Laboratory studies have demonstrated that extreme hemodilution is well tolerated in healthy animals. Animals subjected to acute hemodilution tolerate decreasing hemoglobin concentrations to 30 -50 g/dL, with ischemic changes on electrocardiography and depressed ventricular function below these levels (75, 76) . Because of the high extraction ratio of oxygen in the coronary circulation, coronary blood flow seems to be the major factor, which limits the tolerance of low hemoglobin concentrations. In experimental animal models of coronary stenosis, depressed cardiac function occurs at hemoglobin concentrations between 70 and 100 g/L (76, 77) .
Extensive experience in patients who decline blood for religious reason and in patients with chronic renal disease, myelodysplastic syndromes, and severe autoimmune hemolytic anemias have confirmed that humans tolerate extreme anemia quite well (78 -80) . The best data come from the Jehovah Witness literature (78). Carson and colleagues (81, 82) performed a retrospective cohort study in 1958 patients who underwent surgery and declined blood transfusions for religious reasons. In those patients without cardiovascular disease and with a blood loss of less than 2.0 g/dL, there was no significant increase in perioperative mortality (for baseline hemoglobin of 6 -6.9 g/dL and a decline in hemoglobin of Ͻ2 g/dL the OR for death was 1.4; 95% CI, 0.5-4.2). However, in patients with cardiovascular disease, preoperative anemia was associated with a significant increase in perioperative mortality. These data confirm that humans can adapt to very low hemoglobin levels with cardiovascular disease being the major limiting factor.
In our extensive review of the literature, only a single subgroup from a single study reported a beneficial effect associated with RBC transfusion; elderly patients who suffer a myocardial infarction with a baseline HCT below 33% and who did not undergo revascularization (49). Importantly, patients transfused with a HCT Ͼ36 had a higher mortality. This study has been well criticized for methodologic problems (62) . On the other hand, the study by Rao et al. (50), in patients with acute coronary syndromes found worse outcomes in patients transfused with HCT values greater than 25%. Both the Wu et al. and Rao et al. studies consistently demonstrate that patients who receive RBCs at some higher HCT seem to be harmed by the transfusions. Additional evidence, ideally from a randomized control trial, is still necessary to determine optimal transfusion strategies in this patient population.
Our results suggest that in hemodynamically stable patients without evidence of acute bleeding, limiting blood transfusions may reduce morbidity and mortality. In the absence of acute bleeding, hemoglobin levels consistent with the TRICC trial (7.0 -9.0 g/dL) are well tolerated (6) . Furthermore, current guidelines suggest titrating transfusion requirements to parameters of illness severity while taking into account the individual patients' clinical situation (73, 74) . There remains controversy as to the appropriate transfusion thresholds for patients with ischemic cardiac disease and in the early resuscitation of patients with septic shock (71, 83, 84) .
CONCLUSION
Current data suggest that RBC transfusions are associated with increased morbidity and mortality across heterogenous patient groups. There is sparse evidence that routine RBC transfusion in the nonbleeding patient with a hemoglobin concentration greater than 7.0 g/dL leads to improved outcome. In general, we hold that RBC transfusions are only indicated in hemodynamically stable ICU, trauma, and surgical patients with a hemoglobin concentration below 7 g/dL. However, the need for a RBC transfusion should be individualized based on a patient's clinical circumstances rather than an arbitrary hemoglobin concentration. Additional prospective randomized studies are required to determine the risks and benefits of RBC transfusion, in various disease states, their optimal transfusion triggers, the effects of blood storage time, and leukodepletion, on clinical outcomes. 
